IPP Bureau
GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
By IPP Bureau - November 01, 2024
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
By IPP Bureau - November 01, 2024
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Supriya Lifescience reports 19% revenue increase in Q2 FY25
By IPP Bureau - November 01, 2024
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
PM Modi launches and inaugurates Rs. 12,850 crore health projects at AIIA, New Delhi
By IPP Bureau - October 30, 2024
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
MRP of anti-cancer drugs to come down due to custom duty exemption and GST rate reduction
By IPP Bureau - October 30, 2024
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr
By IPP Bureau - October 30, 2024
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Prime Minister launches expansion of health coverage for citizens of and above 70 years
By IPP Bureau - October 30, 2024
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr
By IPP Bureau - October 28, 2024
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Indoco Remedies posts Q2 FY25 consolidated loss at Rs. 9.57 Cr
By IPP Bureau - October 28, 2024
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr
By IPP Bureau - October 28, 2024
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
AIIMS Delhi hosts workshop on ‘Emerging Technologies for Healthcare’
By IPP Bureau - October 28, 2024
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Aarti Drugs posts Q2 FY25 consolidated profit at Rs. 35.01 Cr
By IPP Bureau - October 26, 2024
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Glenmark Life Sciences posts Q2 FY25 net profit at Rs. 95.31 Cr
By IPP Bureau - October 26, 2024
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Mankind Pharma completes acquisition of BSV
By IPP Bureau - October 25, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr
By IPP Bureau - October 25, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
